Zhu Baorang, Li Jing, Diao Liyan, Ma Ke, Fan Yanna, Yang Wuwei
Department of Oncology Minimally Invasive, The 307th Hospital of PLA, Beijing, China.
Department of Pharmacology, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
J Cancer Res Ther. 2019;15(4):831-835. doi: 10.4103/jcrt.JCRT_408_18.
The aim of this study was to evaluate the efficacy, safety, and survival factors of high-intensity focused ultrasound (HIFU) ablation in the treatment of advanced pancreatic cancer.
A retrospective analysis was conducted between September 2010 and March 2016. Advanced pancreatic cancer patients with HIFU treatment were enrolled in the analysis to evaluate the efficacy of local ablation, pain relief, and relative complications of HIFU therapy. The main factors that affected Overall survival rate (OSR) and median survival time (MST) were also analyzed.
Eighty-six patients received HIFU treatment, with a total of 93 treatments performed, and 83 cases were evaluated. Complete response rate (RR) was 3.6% (3/83) and partial RR was 79.5% (66/83). After HIFU treatment, pain reduction was observed in 74 patients, and the total remission rate was 97.6% (74/76). The total MST was 9.9 months (2-58.7 months), the total OSR in 1 and 2 years was 41.5% and 9.6%, respectively. Minor complications occurred in 97.7% (42/43) patients, including transient fever, abdominal pain, skin burn, and amylase elevation. The univariate analysis showed that the clinical stage, treatment method, ablation efficacy, and combined treatment were significant prognostic factors.
HIFU can significantly alleviate cancer-related pain and prolong the survival time of patients with pancreatic cancer.
本研究旨在评估高强度聚焦超声（HIFU）消融治疗晚期胰腺癌的疗效、安全性及生存因素。
对2010年9月至2016年3月期间的病例进行回顾性分析。纳入接受HIFU治疗的晚期胰腺癌患者，以评估局部消融疗效、疼痛缓解情况及HIFU治疗的相关并发症。同时分析影响总生存率（OSR）和中位生存时间（MST）的主要因素。
86例患者接受了HIFU治疗，共进行93次治疗，其中83例纳入评估。完全缓解率（RR）为3.6%（3/83），部分缓解率为79.5%（66/83）。HIFU治疗后，74例患者疼痛减轻，总缓解率为97.6%（74/76）。总MST为9.9个月（2 - 58.7个月），1年和2年的总OSR分别为41.5%和9.6%。97.7%（42/43）的患者出现轻微并发症，包括短暂发热、腹痛、皮肤灼伤和淀粉酶升高。单因素分析显示，临床分期、治疗方法、消融疗效及联合治疗是显著的预后因素。
HIFU可显著减轻胰腺癌患者的癌痛并延长其生存时间。
